Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.80 |
| ▸ | NR1I2 | O75469 | 6/20 | 0.80 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.80 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 0.80 |
| ▸ | SLC22A11 | Q9NSA0 | 2/20 | 0.80 |
| ▸ | ALB | P02768 | 1/20 | 0.80 |
| ▸ | PPARG | P37231 | 1/20 | 0.80 |
| ▸ | HTR2C | P28335 | 1/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.68 |
| ▸ | APEX1 | P27695 | 2/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.68 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | PKM | P14618 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | RECQL | P46063 | 1/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8973257 | 1.00 | MAPT (0.80) | MAPTNR1I2SLC22A6SLC22A8SLC22A11 | |
| SCHEMBL8973246 | 1.00 | MAPT (0.80) | MAPTNR1I2SLC22A6SLC22A8SLC22A11 | |
| SCHEMBL11072610 | 0.92 | NR1I2 (0.69) | MAPTNR1I2SLC22A6SLC22A8SLC22A11 | |
| SCHEMBL11052519 | 0.92 | MAPT (0.76) | MAPTNR1I2SLC22A6SLC22A8SLC22A11 | |
| Hydrochloric Acid SCHEMBL11013634 | 0.92 | NR1I2 (0.68) | MAPTNR1I2SLC22A6SLC22A8SLC22A11 | |
| SCHEMBL10995455 | 0.91 | MAPT (0.76) | MAPTNR1I2SLC22A6SLC22A8SLC22A11 | |
| SCHEMBL10995438 | 0.91 | MAPT (0.76) | MAPTNR1I2SLC22A6SLC22A8SLC22A11 | |
| SCHEMBL11470237 | 0.91 | MAPT (0.67) | MAPTNR1I2SLC22A6SLC22A8SLC22A11 | |
| SCHEMBL8865950 | 0.90 | NR1I2 (0.85) | MAPTNR1I2SLC22A6SLC22A8SLC22A11 | |
| SCHEMBL10764553 | 0.90 | NR1I2 (0.85) | MAPTNR1I2SLC22A6SLC22A8SLC22A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242863-A1 | Preparation of cefalosporins intermediates and conversion of said intermediates into active compound precursors | MIAT S.P.A. (IT) | 2004-12-02 | — | — | US | claimed |
| US-20040242863-A1 | Preparation of cefalosporins intermediates and conversion of said intermediates into active compound precursors | MIAT S.P.A. (IT) | 2004-12-02 | — | — | US | disclosed |
| US-4201779-A | 7[(2-Amino-thiazol-4-yl)glyoxylamido]-cephem derivatives and processes for their preparation | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-05-06 | — | — | US | disclosed |
| EP-0005785-A1 | Cephalosporin derivatives, process for their preparation, pharmaceutical compositions containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242863-A1 | Preparation of cefalosporins intermediates and conversion of said intermediates into active compound precursors | PCMT1, CYP2S1, DAO | MAPT 4542/4885NR1I2 1906/4885SLC22A6 1742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.